Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis
Review of 42 studies (n=5,326) found that the combination treatments evaluated did not improve overall survival compared with lomustine monotherapy and were often associated with a higher risk of severe adverse events
Source:
Cochrane Database of Systematic Reviews